Teligent, Inc. (NASDAQ:TLGT) Director Carole Ben-Maimon purchased 5,000 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were purchased at an average price of $3.48 per share, for a total transaction of $17,400.00. Following the purchase, the director now owns 2,400 shares of the company’s stock, valued at approximately $8,352. The purchase was disclosed in a filing with the SEC, which is accessible through this link.
Shares of Teligent, Inc. (TLGT) traded up $0.15 during trading on Thursday, hitting $3.51. The stock had a trading volume of 838,157 shares, compared to its average volume of 418,130. The company has a debt-to-equity ratio of 2.23, a quick ratio of 3.71 and a current ratio of 3.28. Teligent, Inc. has a 1 year low of $2.82 and a 1 year high of $9.54.
Teligent (NASDAQ:TLGT) last posted its earnings results on Monday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.07). Teligent had a negative net margin of 16.95% and a negative return on equity of 6.51%. The company had revenue of $13.65 million during the quarter, compared to analysts’ expectations of $19.12 million. During the same quarter last year, the firm earned $0.01 EPS. Teligent’s revenue for the quarter was down 15.5% on a year-over-year basis. sell-side analysts predict that Teligent, Inc. will post -0.13 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/16/insider-buying-teligent-inc-tlgt-director-purchases-17400-00-in-stock.html.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Stifel Financial Corp grew its stake in Teligent by 51.7% in the third quarter. Stifel Financial Corp now owns 1,141,741 shares of the company’s stock valued at $7,685,000 after purchasing an additional 389,307 shares during the last quarter. Elk Creek Partners LLC grew its stake in Teligent by 0.9% in the third quarter. Elk Creek Partners LLC now owns 1,709,841 shares of the company’s stock valued at $11,473,000 after purchasing an additional 15,087 shares during the last quarter. RK Capital Management LLC grew its stake in Teligent by 16.6% in the third quarter. RK Capital Management LLC now owns 583,739 shares of the company’s stock valued at $3,917,000 after purchasing an additional 83,122 shares during the last quarter. Skandinaviska Enskilda Banken AB publ grew its stake in Teligent by 1,023.1% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 121,300 shares of the company’s stock valued at $814,000 after purchasing an additional 110,500 shares during the last quarter. Finally, Wells Fargo & Company MN grew its stake in Teligent by 52.4% in the third quarter. Wells Fargo & Company MN now owns 49,264 shares of the company’s stock valued at $331,000 after purchasing an additional 16,937 shares during the last quarter. Institutional investors own 65.85% of the company’s stock.
Several equities analysts have recently commented on the company. ValuEngine lowered Teligent from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th. BidaskClub lowered Teligent from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Canaccord Genuity assumed coverage on Teligent in a research note on Monday, July 31st. They set a “buy” rating and a $11.00 price target on the stock. Zacks Investment Research upgraded Teligent from a “strong sell” rating to a “hold” rating in a research note on Friday, October 13th. Finally, Roth Capital set a $9.00 price target on Teligent and gave the company a “buy” rating in a research note on Wednesday, August 9th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. Teligent presently has a consensus rating of “Hold” and an average target price of $7.33.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.